This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent approval of TRYNGOLZA™ (olezarsen) for FCS (Familial chylomicronemia syndrome)

Ticker(s): IONS, ARWR

Who's the expert?

Institution: Trinity Health

  • Non invasive cardiologist at Trinity Health (Michigan); fellowship trained at Henry Ford Hospital.
  • Manages 250 patients with severe hypertriglyceridemia; 20-30% of patients that don't achieve desired LDL goals with statins alone.
  • Specializes in heart failure, valvular disease, coronary disease, echocardiography, pericardial disease, arrhythmias and lipid management.

Interview Questions
Q1.

How many FCS patients do you manage?

Added By: wilson_admin
Q2.

Will you prescribe Tryngolza for FCS?

Added By: wilson_admin
Q3.

How much potential is there to expand label to patients with SHTG?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.